TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16035203

Group type: EXPERIMENTAL
Intervention: Activated charcoal-yogurt mixture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Activated charcoal-water slurry
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Activated charcoal with yogurt (in vitro)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Activated charcoal without yogurt (control from previous study)
Number of subjects: 15
Study: 11881903

Group type: EXPERIMENTAL
Intervention: 12 primes presented in lexical decision tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic information
Number of subjects: 0
Study: 10426346

Group type: EXPERIMENTAL
Intervention: Patients in the lowest LVEF quartile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients in the highest LVEF quartile
Number of subjects: 0
Study: 7473439

Group type: EXPERIMENTAL
Intervention: Alternative prenatal care program (8 visits with one of nine study providers)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Usual prenatal care (13 visits with different providers)
Number of subjects: 549
Study: 2265162

Group type: EXPERIMENTAL
Intervention: EMLA (lidocaine 5% and prilocaine 5%) applied for 45 to 60 minutes prior to IV cannulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo applied for 45 to 60 minutes prior to IV cannulation
Number of subjects: 0
Study: 7442597

Group type: EXPERIMENTAL
Intervention: Etofibrate (500 mg, sustained release, 1 capsule per day)
Number of subjects: 404
Study: 31444082

Group type: EXPERIMENTAL
Intervention: Surgical group (mean OSI 7.05 ± 4.65)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nonsurgical group (mean OSI 2.92 ± 1.88)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Optimal OSI cutoff value of 3.2
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Correlation between OSI and CDVA
Number of subjects: 106
Study: 30095476

Group type: EXPERIMENTAL
Intervention: Laparoscopic trans-abdominal preperitoneal (TAPP) repair
Number of subjects: 165

Group type: COMPARATOR
Intervention: Open Lichtenstein repair (OL)
Number of subjects: 165
Study: 26987409

Group type: EXPERIMENTAL
Intervention: Glucose solutions (4%, 16%, 48%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 11
Study: 24790022

Group type: EXPERIMENTAL
Intervention: Saccadic training using King-Devick remediation software
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 0
Study: 22198979

Group type: EXPERIMENTAL
Intervention: CPAP therapy for 3 nights starting the first night after stroke onset, with additional nights based on apnea-hypopnea index results.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CPAP therapy (excellent use)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CPAP therapy (some use)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no CPAP therapy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nursing workload
Number of subjects: 50
Study: 20635803

Group type: EXPERIMENTAL
Intervention: Reiki treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 20
Study: 19127132

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 9965
Study: 17477205

Group type: EXPERIMENTAL
Intervention: High feedback concerning subjects' responsivity to the Cs+ during extinction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low feedback concerning subjects' responsivity to the Cs+ during extinction
Number of subjects: 0
Study: 12601101

Group type: EXPERIMENTAL
Intervention: Parkinson's Disease (PD) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10580624

Group type: EXPERIMENTAL
Intervention: Nasal mupirocin calcium ointment 2% administered twice a day for 5 days followed by twice monthly applications.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nasal mupirocin calcium ointment 2%
Number of subjects: 24
Study: 8718332

Group type: EXPERIMENTAL
Intervention: Randomized clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double blind trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factorial designs
Number of subjects: 0
Study: 1896813

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6223584

Group type: EXPERIMENTAL
Intervention: SPG (20 mg twice a week or 40 mg once a week) with MF protocol (mitomycin C + 5-fluorouracil)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: SPG (20 mg twice a week or 40 mg once a week) with F protocol (tegafur)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: SPG
Number of subjects: 514
Study: 30826311

Group type: EXPERIMENTAL
Intervention: Clotrimazole cream
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tolnaftate solution
Number of subjects: 48
Study: 30696807

Group type: COMPARATOR
Intervention: Placebo aiTBS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Active aiTBS
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham aiTBS
Number of subjects: 45
Study: 27641510

Group type: EXPERIMENTAL
Intervention: Rabeprazole (PPI), 20 mg once daily
Number of subjects: 270

Group type: COMPARATOR
Intervention: Famotidine (H2RA), 40 mg once daily
Number of subjects: 270
Study: 26407169

Group type: EXPERIMENTAL
Intervention: Work rate set to exhaust 70% of W' for 10 minutes (TEN)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Work rate set to exhaust 70% of W' for 3 minutes (THREE)
Number of subjects: 14
Study: 23403717

Group type: EXPERIMENTAL
Intervention: Recombinant human thyrotropin (rhTSH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thyroid hormone withdrawal (THW)
Number of subjects: 60
Study: 21331064

Group type: EXPERIMENTAL
Intervention: Weight loss during pretreatment (≤ ‐1.15% below screening weight)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Weight stable (61% of participants)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Weight gain (≥ +1.15% above screening weight)
Number of subjects: 480
Study: 19761718

Group type: EXPERIMENTAL
Intervention: 25 mg film‐coated tablet of avosentan
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 50 mg film‐coated tablet of avosentan
Number of subjects: 26

Group type: COMPARATOR
Intervention: 10 mg avosentan in 20 ml solution for infusion
Number of subjects: 26
Study: 17567349

Group type: EXPERIMENTAL
Intervention: Ambu AuraOnce Laryngeal Mask
Number of subjects: 50

Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 50
Study: 15319761

Group type: EXPERIMENTAL
Intervention: Chiropractic adjustments with placebo medicine
Number of subjects: 192

Group type: COMPARATOR
Intervention: Muscle relaxants with sham adjustments
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo medicine with sham adjustments
Number of subjects: 192
Study: 11003931

Group type: EXPERIMENTAL
Intervention: Hemodynamic treatment guided by gastric intramucosal pH monitoring
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 34
Study: 8803753

Group type: EXPERIMENTAL
Intervention: Bicaval Wythenshawe technique (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional technique (group B)
Number of subjects: 50
Study: 1389938

Group type: EXPERIMENTAL
Intervention: 30 mg of the 5 mu diameter particle
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg of the 2 mu diameter particle
Number of subjects: 12
Study: 6208841

Group type: EXPERIMENTAL
Intervention: Flecainide (375 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quinidine (660 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (2 doses)
Number of subjects: 12
Study: 30169436

Group type: EXPERIMENTAL
Intervention: Methylphenidate (optimal dose of 40.5 mg, 1.00 mg/kg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 26
Study: 29565947

Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy of the genicular nerves
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional analgesics
Number of subjects: 60
Study: 1300213

Group type: EXPERIMENTAL
Intervention: Analysis of covariance (ANOVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple pre‐post difference scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outcome expressed as percentage of baseline
Number of subjects: 0
Study: 23321182

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally once daily
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg orally twice daily
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 20400412

Group type: EXPERIMENTAL
Intervention: Memantine (40 mg/day or maximum tolerated dose)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 17299464

Group type: EXPERIMENTAL
Intervention: Purple sweet potato (PSP) beverage (200.3 mg anthocyanins per 125 ml per bottle), consumed two bottles per day for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo beverage (1.7 mg anthocyanins per 125 ml per bottle), consumed two bottles per day for 8 weeks
Number of subjects: 38
Study: 15968232

Group type: EXPERIMENTAL
Intervention: Metoclopramide (started at 5 mg daily, titrated to a maximum of 40 mg daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12675976

Group type: EXPERIMENTAL
Intervention: Exposure plus distraction
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Exposure plus focusing
Number of subjects: 48

Group type: COMPARATOR
Intervention: Exposure alone
Number of subjects: 48
Study: 10566623

Group type: EXPERIMENTAL
Intervention: Recombinant human TSH
Number of subjects: 229

Group type: COMPARATOR
Intervention: Thyroid hormone withdrawal
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Combination of radioiodine WBS and serum Tg after recombinant human TSH stimulation
Number of subjects: 229
Study: 9027517

Group type: EXPERIMENTAL
Intervention: Mammographic screening (Two-County study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mammographic screening (Florence programme)
Number of subjects: 0
Study: 1905602

Group type: EXPERIMENTAL
Intervention: Bayesian pharmacokinetic dosing program
Number of subjects: 147

Group type: COMPARATOR
Intervention: Dosing based on physician choice (Control)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Cost savings based on reduced length of stay
Number of subjects: 147
Study: 6333518

Group type: EXPERIMENTAL
Intervention: Prophylactic antibacterial preparation
Number of subjects: 50

Group type: COMPARATOR
Intervention: No prophylactic antibacterial preparation (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antibacterial prophylaxis
Number of subjects: 50
Study: 31264758

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30420920

Group type: EXPERIMENTAL
Intervention: Prepregnancy alcohol use
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Having relatives who use alcohol
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Low education status
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Making local brews as a source of income
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Not having had complications in previous pregnancies
Number of subjects: 365
Study: 27199314

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 20
Study: 24627416

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) adherence in E‐ZES group
Number of subjects: 8709

Group type: COMPARATOR
Intervention: Endeavor zotarolimus‐eluting stent (E‐ZES) without DAPT
Number of subjects: 8709

Group type: COMPARATOR
Intervention: Cypher sirolimus‐eluting stent (C‐SES) without DAPT
Number of subjects: 8709

Group type: EXPERIMENTAL
Intervention: DAPT with E‐ZES
Number of subjects: 8709

Group type: EXPERIMENTAL
Intervention: DAPT with C‐SES
Number of subjects: 8709
Study: 22057018

Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Gaboxadol 20 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 22128453

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 60
Study: 17299108

Group type: EXPERIMENTAL
Intervention: Exercise training for 8 weeks in obese group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 42

Group type: COMPARATOR
Intervention: Obese group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-obese group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AT IL‐18 mRNA content and plasma IL‐18 concentration
Number of subjects: 42
Study: 17931761

Group type: EXPERIMENTAL
Intervention: Marlboro Lights
Number of subjects: 40

Group type: COMPARATOR
Intervention: Marlboro Ultra
Number of subjects: 40
Study: 15189919

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 11303489

Group type: EXPERIMENTAL
Intervention: 4.4 mg beta-carotene from DGLV (n=37, after 18 dropouts)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 1.5 mg beta-carotene from sweet pumpkin (n=36, 18 dropouts)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Vegetables containing virtually no beta-carotene (control) (n=37, 18 dropouts)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: DGLV (4.4 mg beta-carotene)
Number of subjects: 110
Study: 9340061

Group type: EXPERIMENTAL
Intervention: Procollagen III (PIIIP) concentrations in bronchoalveolar lavage fluid (BALF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Procollagen III (PIIIP) concentrations in BALF in patients in II radiological stage
Number of subjects: 24
Study: 8257551

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.6‐1.2 mg per day, sublingually)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clonidine (0.3‐0.9 mg per day, oral)
Number of subjects: 44
Study: 3084315

Group type: EXPERIMENTAL
Intervention: Glibenclamide (7 mg before breakfast and 3.5 mg before supper)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11688590

Group type: EXPERIMENTAL
Intervention: Functional physical therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Reference group physical therapy (normalization of quality of movement)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 31327689

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenalidomide and dexamethasone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone
Number of subjects: 301
Study: 28799076

Group type: EXPERIMENTAL
Intervention: Group music intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-directed music intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 27401338

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched nutritional therapy (peptamen + glutamine)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (peptamen)
Number of subjects: 48
Study: 24641642

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 54

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway Classic
Number of subjects: 54
Study: 22532960

Group type: EXPERIMENTAL
Intervention: Manual triple-headed toothbrush
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual single-headed toothbrush
Number of subjects: 200
Study: 19785609

Group type: EXPERIMENTAL
Intervention: Terbinafine with iontophoretic patch (100 microA cm(‐2))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terbinafine without iontophoresis (passive group)
Number of subjects: 0
Study: 17589423

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15607126

Group type: EXPERIMENTAL
Intervention: Oral NAC 600 mg b.i.d. for 2 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo b.i.d. for 2 months
Number of subjects: 55
Study: 12404705

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (GK501)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginseng (G115)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginkgo-Ginseng combination (320 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginkgo-Ginseng combination (640 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginkgo-Ginseng combination (960 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10102436

Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/d for 1 week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Praziquantel (100 mg/kg in three divided doses at 2‐hour intervals)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 20
Study: 7598284

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg bolus followed by 20-min infusion at 9 micrograms.kg-1.min-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2219614

Group type: EXPERIMENTAL
Intervention: Mesterolone (20 mg daily for 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mesterolone
Number of subjects: 30
Study: 282702

Group type: EXPERIMENTAL
Intervention: Adrenaline as a vasoconstrictor
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Noradrenaline as a vasoconstrictor
Number of subjects: 51
Study: 31618495

Group type: EXPERIMENTAL
Intervention: Taurine
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 30533601

Group type: EXPERIMENTAL
Intervention: CATCH-IT (Competent Adulthood Transition with Cognitive Behavioral Humanistic and Interpersonal Training)
Number of subjects: 369

Group type: COMPARATOR
Intervention: General Health Education (HE)
Number of subjects: 369
Study: 26826543

Group type: EXPERIMENTAL
Intervention: Vacc-4x
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 24894850

Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy (ART) commenced at ≤4 months post radical prostatectomy
Number of subjects: 470

Group type: COMPARATOR
Intervention: Observation with early salvage radiotherapy (SRT) triggered by PSA level >0.20 ng/mL
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy (ART)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Observation with early salvage radiotherapy (SRT)
Number of subjects: 470
Study: 21630047

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 282

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 282
Study: 20645280

Group type: EXPERIMENTAL
Intervention: Treatment satisfaction data from four treatment arms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta likelihood ratio test
Number of subjects: 0
Study: 17049197

Group type: EXPERIMENTAL
Intervention: Sodium ferulate, determined using HPLC-ESI-MS method
Number of subjects: 20
Study: 16260426

Group type: EXPERIMENTAL
Intervention: Monascus purpureus Went rice (600 mg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 14624833

Group type: COMPARATOR
Intervention: Task-specific self-instruction intervention for handwriting (3 months, individual basis)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Task-specific self-instruction intervention for handwriting (6 months, group setting)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 7
Study: 11185676

Group type: EXPERIMENTAL
Intervention: Azithromycin 1200 mg oral dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nelfinavir 750 mg q8h for 11 days with concurrent azithromycin 1200 mg on Day 9
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both dosing regimens
Number of subjects: 12
Study: 8685657

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 803

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 803
Study: 1825266

Group type: EXPERIMENTAL
Intervention: Fenoterol, 100 micrograms/dose
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fenoterol, 200 micrograms/dose
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fenoterol, 50 micrograms and ipratropium, 20 micrograms/dose in a single inhaler (Berodual)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fenoterol, 100 micrograms and ipratropium, 40 micrograms/dose in a single inhaler (Duovent)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-dose combination
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose fenoterol and low-dose combination
Number of subjects: 120
Study: 6341842

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Dextrose)
Number of subjects: 40
Study: 29552984

Group type: EXPERIMENTAL
Intervention: Edoxaban plus aspirin
Number of subjects: 203

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 203
Study: 27846071

Group type: EXPERIMENTAL
Intervention: Partial ARV adherence (81%-98%)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Near perfect ARV adherence (>98%)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Detectable breastmilk RNA (≥40 copies/mL)
Number of subjects: 263
Study: 25230136

Group type: EXPERIMENTAL
Intervention: Waterjet-assisted ESD
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventional ESD
Number of subjects: 117